ClinicalTrials.gg
RecruitingNCT06287762Updated Nov 19, 2026

A Natural History Study of RYR1-Related Disorders

An observational study in Ryanodine Receptor 1-Related Myopathy and Ryanodine Receptor 1 Related Disorders, sponsored by National Institutes of Health Clinical Center (CC). Recruiting at 1 site in United States. Open to participants aged 7 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by National Institutes of Health Clinical Center (CC) · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
7 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Muscular Diseases with a site in United States — 19 open to participants now, 27 under way, 5 of them phase 3. Muscular Diseases · United States.

Planned enrollment
11th of 30
150 · median 70
Started
2025
with 5 others
Observational
31 of 99
9 open now
Primary completion
2031-04
later than 22 of 25 live
Registered
83rd of 99
by date

Among the 99 studies in Muscular Diseases with a site in United States, this one is the 11th largest by planned enrollment of the 30 observational ones that give a count, is one of 6 that started in 2025, is one of 31 observational ones, reaches primary completion later than 22 of the 25 other live ones, and was the 83rd registered.

Muscular Diseases

232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.

Browse Muscular Diseases studies →

Open to participants now

19 of the 99 studies in Muscular Diseases with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 7 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Muscular Diseases with a site in United States, or all of them as a file.
02

Study summary

Background:

Congenital myopathies (CM) are genetic disorders that can cause decreased muscle tone and muscle weakness. Most CMs in the United States are related to the ryanodine receptor 1 (RYR1) gene. Researchers need more natural history data to learn about these CMs in children and adults.

Objective:

To learn more about the signs, symptoms, and course of RYR1-related disorders.

Eligibility:

People aged 7 years and older with an RYR1-related disorder.

Design:

Ambulatory participants will come to the Clinical Center and non-ambulatory participants will visit via telehealth.

Visits will be once a year for 3 or 5 years. Clinical Center visits will take 2 to 3 days.

All participants will undergo tests including:

Photos and videos. These will be taken to document the participant s condition.

Blood and urine tests.

Activity Tracker. Participants will wear a device to record their activity.

Questionnaires. Participants will answer questions about their health, pain, fatigue, stress, quality of life, and other topics.

Participants who visit the Clinical Center will also undergo:

Tests of heart and lung function.

Motor skills and strength tests. Participants will walk, climb stairs, kneel, crawl, stand up, and perform other movements to test their strength and abilities. They will squeeze and pinch a handheld device to test their grip.

Imaging scans.

Skin biopsy. Adult participants may opt to have a sample of skin taken (one time only).

Eye exam

Read the detailed description

STUDY DESCRIPTION:

This prospective natural history study seeks to characterize the clinical manifestations and course of Ryanodine Receptor 1 -related disorders (RYR1-RD). RYR1-RD include a wide range of rare congenital and adult-onset neuromuscular phenotypes that are typically slowly progressive. The study is observational and comprises a primary data collection phase (Years 1-3) and extended follow-up phase (Years 4-5), stratified into centralized (ambulatory) and decentralized (non-ambulatory) arms. During each phase, there will be one visit per year. The study will enhance the foundational knowledge of RYR1-RD and support clinical trial readiness.

OBJECTIVE:

Primary:

Characterize phenotype and disease course over a three-year period

Secondary:

Characterize phenotype and disease course over an extended (2-year) period (total 5 years)

Exploratory:

  1. Investigate potential biomarkers of disease status and progression
  2. Explore clinical meaningfulness thresholds for research assessments
  3. Extract common data elements from existing medical records (real-world evidence)

    ENDPOINTS:

    Primary:

    Change from baseline to Year 3 in:

    Motor function and performance

    • Motor Function Measure (MFM) sub-domains (percent of maximum score)
    • Six-minute walk test (meters travelled with percent predicted)
    • Timed functional tests (ascend four stairs, descend four stairs, supine to stand) (seconds)
    • Grip and pinch strength (kg and percent predicted)
    • Performance of Upper Limb (PUL)
    • Accelerometry (wearable sensor)
    • Quantitative muscle assessment
    • Brooke and Vignos assessment

    Pulmonary function

    • Forced vital capacity (percent reference norm)
    • Forced expiratory volume at 1 second (percent reference norm)
    • Slow vital capacity (Liters)
    • Maximal voluntary ventilation (Liters)
    • Maximum inspiratory pressure (MIP)
    • Maximum expiratory pressure (MEP)

    Patient-reported outcomes

    • PROMIS-57 Profile (subscale and overall t-scores); adults - depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and satisfaction with participation in social roles
    • PROMIS Ped-25 Profile (subscale and overall t-scores); 8 - 17 y
    • PROMIS Parent Proxy 25 Profile - Fatigue, physical stress experiences, positive affect and wellbeing, psychological stress experiences, anxiety/fear, physical function, pain; 5 - 7 y
    • PROMIS Upper Extremity - Short Form 7a
    • PROMIS Pediatric Upper Extremity - Short Form 8a
    • PROMIS Parent Proxy Upper Extremity - Short Form 8a
    • Physical Activity Questionnaire for Children (PAQ-C); 8 - 13 y
    • Physical Activity Questionnaire for Adolescents (PAQ-A); 14 - 17 y
    • International physical activity questionnaire (IPAQ); adults

    Ophthalmology

    • Visual acuity
    • Dilated ophthalmology exam at baseline only
    • Extraocular motility assessment
    • Marginal reflex distance (Ptosis)
    • Optical Coherence Tomography
    • Ancillary testing, imaging, and repeat dilated exams as indicated, based on assessment and discretion of clinician

    Secondary:

    Change from baseline to Year 5 in:

    Motor function and performance

    • Motor Function Measure (MFM) sub-domains (percent of maximum score)
    • Six-minute walk test (meters travelled with percent predicted)
    • Timed functional tests (ascend four stairs, descend four stairs, supine to stand) (seconds)
    • Grip and pinch strength (kg and percent predicted)
    • Performance of Upper Limb (PUL)
    • Accelerometry (wearable sensor)
    • Quantitative muscle assessment
    • Brooke and Vignos assessment

    Pulmonary function

    • Forced vital capacity (percent reference norm)
    • Forced expiratory volume at 1 second (percent reference norm)
    • Slow vital capacity (Liters)
    • Maximal voluntary ventilation (Liters)
    • Maximum inspiratory pressure (MIP)
    • Maximum expiratory pressure (MEP)

    Patient-reported outcomes

    • PROMIS-57 Profile (subscale and overall t-scores); adults - depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and satisfaction with participation in social roles
    • PROMIS Ped-25 Profile (subscale and overall t-scores); 8 - 17 y
    • PROMIS Parent Proxy -25 Profile Fatigue, physical stress experiences, positive affect and wellbeing, psychological stress experiences, anxiety/fear, physical function, pain; 5 - 7 y
    • PROMIS Upper Extremity - Short Form 7a
    • PROMIS Pediatric Upper Extremity - Short Form 8a
    • PROMIS Parent Proxy Upper Extremity - Short Form 8a
    • Physical Activity Questionnaire for Children (PAQ-C); 8 - 13 y
    • Physical Activity Questionnaire for Adolescents (PAQ-A); 14 - 17 y
    • International physical activity questionnaire (IPAQ); adults

    Ophthalmology

    • Visual acuity
    • Dilated ophthalmology exam at baseline only
    • Extraocular motility assessment
    • Marginal reflex distance (Ptosis)
    • Optical Coherence Tomography
    • Ancillary testing, imaging, and repeat dilated exams as indicated, based on assessment and discretion of clinician

    Exploratory:

    Biomarkers

    Including but not limited to:

    • Plasma NAD plus, NADH
    • Plasma GSH, GSSG
    • Plasma cytokines
    • Serum creatine phosphokinase
    • Urine and plasma 15-F2t isoprostane
    • Urine 8OHdG
    • PBMC (Peripheral Blood Mononuclear Cell)
    • Near infrared spectroscopy (muscle tissue oxygenation)
    • Dixon MRI of lower extremity
    • Optional skin punch biopsy (fibroblast culture)
    • Muscle ultrasound
    • Electrical impedance myography (EIM)
03

Conditions studied

  • Ryanodine Receptor 1-Related Myopathy
  • Ryanodine Receptor 1 Related Disorders

Keywords

  • RYR1
  • Muscle Disease
  • Natural History
  • Congenital Myopathy
04

Who can participate

Ages eligible
7 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total of 150 clinically stable adults and children (7 years of age or older) with genetically confirmed RYR1-RD.

Eligibility criteria

  • INCLUSION CRITERIA (CENTRALIZED ARM)

    1. Stated willingness to comply with all study procedures, availability for the duration of the study, and submission of medical records to research team prior to screening.
    2. Male or female, aged >=7 years of age.
    3. Genetically confirmed RYR1-related disorder, evidenced by pathogenic or likely pathogenic variants identified by CLIA testing (whole genome, exome, targeted, partial or full RYR1 sequencing) OR variant of uncertain significance with supporting clinical phenotype.
    4. Agreement to adhere to Lifestyle Considerations throughout study duration.
    5. Ability of subject to communicate their understanding of the purpose of the study, and willingness to provide assent and/or to sign a written document.
    6. Resides in the United States.

EXCLUSION CRITERIA (CENTRALIZED ARM)

  1. Participation in an IND, IDE, or equivalent clinical study in the past six months
  2. Severe disability or mobility issues (inability to walk 10 meters with or without assistance)
  3. Requires mechanical ventilation or tracheotomy
  4. Other neuromuscular diseases resulting in muscle weakness
  5. Ongoing medical condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study (e.g. active infection) or safety of the subject.

INCLUSION CRITERIA (DE-CENTRALIZED ARM)

  1. Stated willingness to comply with all study procedures, availability for the duration of the study, and submission of medical records to research team prior to screening.
  2. Male or female, aged > 7 years of age.
  3. Genetically confirmed RYR1-related disorder, evidenced by pathogenic or likely pathogenic variants identified by CLIA testing (whole genome, exome, targeted, partial or full RYR1 sequencing) OR variant of uncertain significance with supporting clinical phenotype.
  4. Ability of subject to communicate their understanding of the purpose of the study, and willingness to provide assent and/or sign a written informed consent document.
  5. Resides in the United States

EXCLUSION CRITERIA (DE-CENTRALIZED ARM)

  1. Participation in an IND, IDE, or equivalent clinical study in the past six months
  2. Other neuromuscular diseases resulting in muscle weakness
  3. Ongoing medical condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study (e.g. active infection) or safety of the subject
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)

Groups and cohorts

  • Centralized

    Visits are conducted at the NIH clinical center. All participants are ambulatory.

  • Decentralized

    Visits are conducted via telehealth.

06

What researchers measure

Primary outcomes

  1. Adverse and disease-related events

    Serious (21CFR312.32) adverse events:- Narrative description (clinician)- Causality assessment (related or unrelated to disease)- CTCAE system organ class- CTCAE lower-level term- Falls questionnaire; adults

    Time frame: 3 years

  2. Medical data review

    \- Demographics- Developmental history- Medical history- Social determinants of health (environmental conditions such as economic stability, health care and education access and quality, neighborhood and built environment, and social and community context.- Full physical exam- Review of genetic diagnostic report/results- Prior medical records

    Time frame: 3 years

  3. Ophthalmology

    \- Marginal reflex distance (Ptosis)- Binocular horizontal visual field test- Optical Coherence Tomography- Goldmann Perimetry Degrees: lateral rectus, superior rectus, inferior oblique, medial rectus, superior oblique, inferior rectus

    Time frame: 3 years

  4. Patient-reported outcomes

    \- PROMIS-57 Profile (subscale and overall t-scores); adults - depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and satisfaction with participation in social roles- PROMIS Ped-25 Profile (subscale and overall t-scores); 8 - 17 y- PROMIS Parent Proxy 25 Profile - Fatigue, physical stress experiences, positive affect and wellbeing, psychological stress experiences, anxiety/fear, physical function, pain; 5 - 7 y- PROMIS Upper Extremity - Short Form 7a- PROMIS Pediatric Upper Extremity - Short Form 8a- PROMIS Parent Proxy Upper Extremity - Short Form 8a- Physical Activity Questionnaire for Children (PAQ-C); 8 - 13 y- Physical Activity Questionnaire for Adolescents (PAQ-A); 14 - 17 y- International physical activity questionnaire (IPAQ); adults

    Time frame: 3 years

  5. Pulmonary function

    \- Forced vital capacity (% reference norm)- Forced expiratory volume at 1 second (% reference norm) - Slow vital capacity (Liters)- Maximal voluntary ventilation (Liters)- Maximum inspiratory pressure (MIP)- Maximum expiratory pressure (MEP)

    Time frame: 3 years

  6. Motor function and performance

    \- Motor Function Measure (MFM) sub-domains (percent of maximum score)- Six-minute walk test (meters travelled with percent predicted)- Timed functional tests (ascend four stairs, descend four stairs, supine to stand) (seconds)- Grip and pinch strength (kg and percent predicted)- Performance of Upper Limb (PUL)- Accelerometry (wearable sensor)- Quantitative muscle assessment- Brooke and Vignos assessment

    Time frame: 3 years

Secondary outcomes

  1. Characterize phenotype and disease course over an extended (2-year) period (total 5 years).Collect exploratory biomarker data.

    (1) Investigate potential biomarkers of disease status and progression(2) Explore clinical meaningfulness thresholds for research assessments(3) Extract common data elements from existing medical records (real-world evidence)

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2031, 73 months after the start.

Of 36 observational studies under Muscular Diseases, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 159. This study's planned 73 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Mar 1, 2024
StartActual
Mar 11, 2025
Primary completionEst.
Apr 30, 2031
CompletionEst.
Dec 30, 2031
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • National Institutes of Health Clinical Center · Bethesda, United StatesContact •••8884→•••9808
Oct 15, 2026
Show all 4 updates
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: verification date
  2. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date
  3. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  4. Oct 15, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • National Institutes of Health Clinical Center · Bethesda, United StatesContact •••8884→•••9808
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06287762
Responsible party
Sponsor
First posted
Mar 1, 2024
Start date
Mar 11, 2025
Primary completion
Apr 30, 2031 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Nov 19, 2026

Study contacts

Irene C Chrismer, R.N.
Contact
irene.chrismer@nih.gov
(240) 856-9808
Tokunbor A Lawal, C.R.N.P.
Contact
lawalt@mail.nih.gov
(301) 451-5951
Tokunbor A Lawal, C.R.N.P.
principal investigator · National Institutes of Health Clinical Center (CC)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion